The DOI matches its Crossref record; 272 of the 272 references it cites were found in a registry or an index.
RNAi-based therapeutics and tumor targeted delivery in cancer
Abstract
Over the past decade, non-coding RNA-based therapeutics have proven as a great potential for the development of targeted therapies for cancer and other diseases. The discovery of the critical function of microRNAs (miRNAs) has generated great excitement in developing miRNA-based therapies. The dysregulation of miRNAs contributes to the pathogenesis of various human diseases and cancers by modulating genes that are involved in critical cellular processes, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, drug resistance, and tumorigenesis. miRNA (miRNA mimic, anti-miRNA/antagomir) and small interfering RNA (siRNA) can inhibit the expression of any cancer-related genes/mRNAs with high specificity through RNA interference (RNAi), thus representing a remarkable therapeutic tool for targeted therapies and precision medicine. siRNA and miRNA-based therapies have entered clinical trials and recently three novel siRNA-based therapeutics were approved by the Food and Drug Administration (FDA), indicating the beginning of a new era of targeted therapeutics. The successful clinical applications of miRNA and siRNA therapeutics rely on safe and effective nanodelivery strategies for targeting tumor cells or tumor microenvironment. For this purpose, promising nanodelivery/nanoparticle-based approaches have been developed using a variety of molecules for systemic administration and improved tumor targeted delivery with reduced side effects. In this review, we present an overview of RNAi-based therapeutics, the major pharmaceutical challenges, and the perspectives for the development of promising delivery systems for clinical translation. We also highlight the passive and active tumor targeting nanodelivery strategies and primarily focus on the current applications of nanoparticle-based delivery formulations for tumor targeted RNAi molecules and their recent advances in clinical trials in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207247 · Cited by 211
RetractedHou, Y., Li, F., & Li, H. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.11.019 · Cited by 22
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanoparticle-mediated cellular response is size-dependent
Jiang, W., Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.30 · Cited by 2,776
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990
A promoter-level mammalian expression atlas
The FANTOM Consortium and the RIKEN PMI and CLST (DGT) (2014) · Nature · doi:10.1038/nature13182 · Cited by 1,982
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi
Martinez, J., Patkaniowska, A., Urlaub, H., Lührmann, R., & Tuschl, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00908-x · Cited by 1,459
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., Teruya-Feldstein, J., Reinhardt, F., Onder, T. T., Valastyan, S., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2024 · Cited by 1,336
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
CD44: Structure, Function and Association with the Malignant Process
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60101-3 · Cited by 1,016
Regulatory Mechanism of MicroRNA Expression in Cancer
Ali Syeda, Z., Langden, S. S. S., Munkhzul, C., Lee, M., & Song, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051723 · Cited by 995
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J.-L., Kim, T.-Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 975
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Self-citationThe transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
The Potential for microRNA Therapeutics and Clinical Research
Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 726
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
On the road to reading the RNA-interference code
Siomi, H., & Siomi, M. C. (2009) · Nature · doi:10.1038/nature07754 · Cited by 675
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
Sykes, E. A., Chen, J., Zheng, G., & Chan, W. C. W. (2014) · ACS Nano · doi:10.1021/nn500299p · Cited by 635
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
Reddy, K. B. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0185-1 · Cited by 613
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Gold Nanoparticles for Nucleic Acid Delivery
Ding, Y., Jiang, Z., Saha, K., Kim, C. S., Kim, S. T., Landis, R. F., & Rotello, V. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.30 · Cited by 521
Exploring miRNA based approaches in cancer diagnostics and therapeutics
Mishra, S., Yadav, T., & Rani, V. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.003 · Cited by 493
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
An overview of targeted cancer therapy
Padma, V. V. (2015) · BioMedicine · doi:10.7603/s40681-015-0019-4 · Cited by 459
Platt, V. M., & Szoka, F. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800024g · Cited by 456
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Self-citationLiposomal siRNA nanocarriers for cancer therapy
Ozpolat, B., Sood, A. K., & Lopez-Berestein, G. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.008 · Cited by 442
Self-citationMicroRNA delivery through nanoparticles
Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.007 · Cited by 437
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Fang, C., Shi, B., Pei, Y.-Y., Hong, M.-H., Wu, J., & Chen, H.-Z. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.08.002 · Cited by 424
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Small non-coding RNA and cancer
Romano, G., Veneziano, D., Acunzo, M., & Croce, C. M. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx026 · Cited by 423
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165210 · Cited by 410
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Control of polymeric nanoparticle size to improve therapeutic delivery
Hickey, J. W., Santos, J. L., Williford, J.-M., & Mao, H.-Q. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.006 · Cited by 379
Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration
Zhou, Z., Liu, X., Zhu, D., Wang, Y., Zhang, Z., Zhou, X., Qiu, N., Chen, X., & Shen, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.021 · Cited by 379
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
Prospects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T.-C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Seto, A. G., Beatty, X., Lynch, J. M., Hermreck, M., Tetzlaff, M., Duvic, M., & Jackson, A. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15547 · Cited by 333
RNA interference-based therapy and its delivery systems
Chen, X., Mangala, L. S., Rodriguez-Aguayo, C., Kong, X., Lopez-Berestein, G., & Sood, A. K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9717-6 · Cited by 329
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
Juliano, R., Bauman, J., Kang, H., & Ming, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900093r · Cited by 304
Virus-mediated gene delivery for human gene therapy
Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302
Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T. (2014) · Gene · doi:10.1016/j.gene.2013.12.019 · Cited by 301
miRNA nanotherapeutics for cancer
Ganju, A., Khan, S., Hafeez, B. B., Behrman, S. W., Yallapu, M. M., Chauhan, S. C., & Jaggi, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.014 · Cited by 298
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-E., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 294
Aleku, M., Schulz, P., Keil, O., Santel, A., Schaeper, U., Dieckhoff, B., Janke, O., Endruschat, J., Durieux, B., Röder, N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2428 · Cited by 293
Scott, L. J., & Keam, S. J. (2021) · Drugs · doi:10.1007/s40265-020-01463-0 · Cited by 292
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Hansen, A. E., Petersen, A. L., Henriksen, J. R., Boerresen, B., Rasmussen, P., Elema, D. R., Rosenschöld, P. M. A., Kristensen, A. T., Kjær, A., & Andresen, T. L. (2015) · ACS Nano · doi:10.1021/acsnano.5b01324 · Cited by 277
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., Williams, M., Wright, C., Edelman, J. J. B., Vallely, M. P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt412 · Cited by 275
Direct in Vivo RNAi Screen Unveils Myosin IIa as a Tumor Suppressor of Squamous Cell Carcinomas
Schramek, D., Sendoel, A., Segal, J. P., Beronja, S., Heller, E., Oristian, D., Reva, B., & Fuchs, E. (2014) · Science · doi:10.1126/science.1248627 · Cited by 273
Advances in siRNA delivery in cancer therapy
Singh, A., Trivedi, P., & Jain, N. K. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1307210 · Cited by 271
Epigenetic heterogeneity in cancer
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019) · Biomarker Research · doi:10.1186/s40364-019-0174-y · Cited by 270
Chitosan-based siRNA delivery systems
Ragelle, H., Vandermeulen, G., & Préat, V. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.005 · Cited by 261
Nanotoxicity: A Key Obstacle to Clinical Translation of siRNA-Based Nanomedicine
Xue, H. Y., Liu, S., & Wong, H. L. (2014) · Nanomedicine · doi:10.2217/nnm.13.204 · Cited by 250
Therapeutic targeting of non-coding RNAs in cancer
Slaby, O., Laga, R., & Sedlacek, O. (2017) · Biochemical Journal · doi:10.1042/bcj20170079 · Cited by 248
Tumor-targeted nanomedicines for cancer theranostics
Arranja, A. G., Pathak, V., Lammers, T., & Shi, Y. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.014 · Cited by 246
Challenges identifying efficacious miRNA therapeutics for cancer
Segal, M., & Slack, F. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1765770 · Cited by 244
RNA therapeutics: RNAi and antisense mechanisms and clinical applications
Chery, J. (2016) · Postdoc Journal · doi:10.14304/surya.jpr.v4n7.5 · Cited by 240
Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors
Wang, H., Jiang, Y., Peng, H., Chen, Y., Zhu, P., & Huang, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.031 · Cited by 231
Zhu, L., Perche, F., Wang, T., & Torchilin, V. P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.060 · Cited by 220
Hussain, Z., Khan, S., Imran, M., Sohail, M., Shah, S. W. A., & de Matas, M. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00631-4 · Cited by 220
Nanomedicine based approaches for the delivery of siRNA in cancer
Ozpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02191.x · Cited by 218
Self-citationAhmadzada, T., Reid, G., & McKenzie, D. R. (2018) · Biophysical Reviews · doi:10.1007/s12551-017-0392-1 · Cited by 214
EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma
Thaker, P. H., Deavers, M., Celestino, J., Thornton, A., Fletcher, M. S., Landen, C. N., Kinch, M. S., Kiener, P. A., & Sood, A. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0589 · Cited by 211
Clemons, T. D., Singh, R., Sorolla, A., Chaudhari, N., Hubbard, A., & Iyer, K. S. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b02946 · Cited by 211
A review of the current status of siRNA nanomedicines in the treatment of cancer
Resnier, P., Montier, T., Mathieu, V., Benoit, J.-P., & Passirani, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.060 · Cited by 210
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Zhou, J., Shum, K.-T., Burnett, J., & Rossi, J. (2013) · Pharmaceuticals · doi:10.3390/ph6010085 · Cited by 205
Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Wang, J., Sui, M., & Fan, W. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110827 · Cited by 205
Hak, S., Helgesen, E., Hektoen, H. H., Huuse, E. M., Jarzyna, P. A., Mulder, W. J. M., Haraldseth, O., & Davies, C. D. L. (2012) · ACS Nano · doi:10.1021/nn301630n · Cited by 204
Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B. R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R. P., Erbe, D., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 201
Passive and Active Tumour Targeting with Nanocarriers
Hirsjärvi, S., Passirani, C., & Benoît, J. (2011) · Current Drug Discovery Technologies · doi:10.2174/157016311796798991 · Cited by 200
The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market
Titze-de-Almeida, R., David, C., & Titze-de-Almeida, S. S. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2134-2 · Cited by 200
Lipid nanoparticle delivery systems for siRNA-based therapeutics
Wan, C., Allen, T. M., & Cullis, P. R. (2014) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0161-z · Cited by 193
Huang, X., Schwind, S., Yu, B., Santhanam, R., Wang, H., Hoellerbauer, P., Mims, A., Klisovic, R., Walker, A. R., Chan, K. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3191 · Cited by 193
Ahmad, A., Khan, F., Mishra, R. K., & Khan, R. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00511 · Cited by 186
Efficient nanocarriers of siRNA therapeutics for cancer treatment
Subhan, M. A., & Torchilin, V. P. (2019) · Translational Research · doi:10.1016/j.trsl.2019.07.006 · Cited by 183
Yue, J., Feliciano, T. J., Li, W., Lee, A., & Odom, T. W. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00252 · Cited by 181
Wang, Y., Xie, Y., Kilchrist, K. V., Li, J., Duvall, C. L., & Oupický, D. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b21214 · Cited by 175
Lai, X., Eberhardt, M., Schmitz, U., & Vera, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz638 · Cited by 170
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Daige, C. L., Wiggins, J. F., Priddy, L., Nelligan-Davis, T., Zhao, J., & Brown, D. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0209 · Cited by 168
RNAi-based nanomedicines for targeted personalized therapy
Daka, A., & Peer, D. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.014 · Cited by 167
RNAi screens in mice identify physiological regulators of oncogenic growth
Beronja, S., Janki, P., Heller, E., Lien, W.-H., Keyes, B. E., Oshimori, N., & Fuchs, E. (2013) · Nature · doi:10.1038/nature12464 · Cited by 164
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Bartlett, D. W., & Davis, M. E. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21668 · Cited by 164
Anastasiadou, E., Seto, A. G., Beatty, X., Hermreck, M., Gilles, M.-E., Stroopinsky, D., Pinter‐Brown, L. C., Pestano, L. A., Marchese, C., Avigan, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3139 · Cited by 163
Nanoparticle-siRNA: A potential cancer therapy?
Young, S. W. S., Stenzel, M., & Jia-Lin, Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.015 · Cited by 161
Lipidic Systems for In Vivo siRNA Delivery
Wu, S. Y., & McMillan, N. A. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9140-1 · Cited by 160
Heidel, J. D., Liu, J. Y.-C., Yen, Y., Zhou, B., Heale, B. S. E., Rossi, J. J., Bartlett, D. W., & Davis, M. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2218 · Cited by 160
Cabral, H., Makino, J., Matsumoto, Y., Mi, P., Wu, H., Nomoto, T., Toh, K., Yamada, N., Higuchi, Y., Konishi, S., et al. (2015) · ACS Nano · doi:10.1021/nn5070259 · Cited by 159
RNA-targeted therapeutics in cancer clinical trials: Current status and future directions
Barata, P. C., Sood, A. K., & Hong, D. S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.004 · Cited by 159
Chemical and structural modifications of RNAi therapeutics
Ku, S. H., Jo, S. D., Lee, Y. K., Kim, K., & Kim, S. H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.015 · Cited by 155
Strumberg, D., Schultheis, B. S., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J., & Drevs, J. (2011) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp50076 · Cited by 149
Knies, U. E., Fox, S. B., Poulsom, R., Evan, G. I., & Harris, A. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3176 · Cited by 142
Nagy, A., & Schally, A. V. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.043489 · Cited by 141
Affinity binding phenomena of DNA onto apatite crystals
Okazaki, M., Yoshida, Y., Yamaguchi, S., Kaneno, M., & Elliott, J. C. (2001) · Biomaterials · doi:10.1016/s0142-9612(00)00433-6 · Cited by 140
Bayraktar, R., Pichler, M., Kanlikilicer, P., Ivan, C., Bayraktar, E., Kahraman, N., Aslan, B., Oğuztüzün, S., Ulaşlı, M., Arslan, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14264 · Cited by 140
Yang, C., Gao, S., Dagnæs‐Hansen, F., Jakobsen, M., & Kjems, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b16556 · Cited by 139
Gaur, S., Wen, Y., Song, J. H., Parikh, N. U., Mangala, L. S., Blessing, A. M., Ivan, C., Wu, S. Y., Varkaris, A. S., Shi, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4971 · Cited by 138
Endosomal Escape Pathways for Non-Viral Nucleic Acid Delivery Systems
Liang, W., & Lam, J. K. W. (2012) · InTech eBooks · doi:10.5772/46006 · Cited by 137
Zhang, C.-G., Zhu, W.-J., Liu, Y., Yuan, Z.-Q., Yang, S.-D., Chen, W.-L., Li, J., Zhou, X., Liu, C., & Zhang, X. (2016) · Scientific Reports · doi:10.1038/srep23859 · Cited by 137
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Wagner, M. J., Mitra, R., McArthur, M. J., Baze, W. B., Barnhart, K. F., Wu, S. Y., Rodriguez‐Aguayo, C., Zhang, X., Coleman, R. L., Lopez‐Berestein, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0541 · Cited by 137
Lipid-Based Nanoparticles in The Systemic Delivery of siRNA
Lin, Q., Chen, J., Zhang, Z., & Zheng, G. (2013) · Nanomedicine · doi:10.2217/nnm.13.192 · Cited by 136
miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma
Chang, R., Xiao, S., Lei, X., Yang, H., Fang, F., & Yang, L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0851 · Cited by 132
Garbuzenko, O. B., Kuzmov, A., Taratula, O., Pine, S. R., & Minko, T. (2019) · Theranostics · doi:10.7150/thno.39816 · Cited by 132
Micelle-like Nanoparticles as Carriers for DNA and siRNA
Navarro, G., Pan, J., & Torchilin, V. P. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5007213 · Cited by 130
Dika, I. E., Lim, H. Y., Yong, W. P., Lin, C., Yoon, J., Modiano, M., Freilich, B. L., Choi, H. J., Chao, T.-Y., Kelley, R. K., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0838 · Cited by 130
Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Reyes‐González, J. M., Armaiz-Peña, G. N., Mangala, L. S., Valiyeva, F., Ivan, C., Pradeep, S., Echevarría-Vargas, I. M., Rivera-Reyes, A., Sood, A. K., & Vivas‐Mejía, P. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0801 · Cited by 129
Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.36 · Cited by 128
Tekedereli, İ., Alpay, S. N., Tavares, C. D. J., Cobanoglu, Z. E., Kaoud, T. S., Şahin, İ. H., Sood, A. K., Lopez‐Berestein, G., Dalby, K. N., & Özpolat, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041171 · Cited by 128
Cancer nanomedicine: Addressing the dark side of the enhanced permeability and retention effect
Huynh, E., & Zheng, G. (2015) · Nanomedicine · doi:10.2217/nnm.15.86 · Cited by 125
Progress and perspective of inorganic nanoparticle-based siRNA delivery systems
Jiang, Y. Y., Huo, S., Hardie, J. M., Liang, X., & Rotello, V. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1134486 · Cited by 125
Challenges and opportunities for siRNA-based cancer treatment
Wang, T., Shigdar, S. L., Shamaileh, H. A., Gantier, M. P., Yin, W., Xiang, D., Wang, L., Zhou, S.-F., Hou, Y., Wang, P., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.045 · Cited by 123
Zhang, W., Xu, W., Lan, Y., He, X., Liu, K., & Liang, Y. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s203113 · Cited by 123
Liposomal cancer therapy: exploiting tumor characteristics
Kaasgaard, T., & Andresen, T. L. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903427940 · Cited by 122
Noblitt, L. W., Bangari, D. S., Shukla, S., Knapp, D. W., Mohammed, S. I., Kinch, M. S., & Mittal, S. K. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700761 · Cited by 121
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
Hamurcu, Z., Ashour, A. A., Kahraman, N., & Özpolat, B. (2016) · Oncotarget · doi:10.18632/oncotarget.7672 · Cited by 118
Lipid nanocarriers for microRNA delivery
Scheideler, M., Vidaković, I., & Prassl, R. (2019) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2019.104837 · Cited by 117
Danhier, F., Messaoudi, K., Lemaire, L. P., Benoît, J., & Lagarce, F. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.051 · Cited by 114
Recent advances of siRNA delivery by nanoparticles
Yuan, X., Naguib, S., & Wu, Z. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.559223 · Cited by 113
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1160882 · Cited by 113
Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy
Wu, P., Opadele, A. E., Onodera, Y., & Nam, J. (2019) · Cancers · doi:10.3390/cancers11111783 · Cited by 112
Luo, X., Peng, X., Hou, J., Wu, S., Shen, J., & Wang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s137245 · Cited by 111
Dufès, C., Al Robaian, M., & Somani, S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.21 · Cited by 110
Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Santel, A., Aleku, M., Röder, N., Möpert, K., Durieux, B., Janke, O., Keil, O., Endruschat, J., Dames, S., Lange, C. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1994 · Cited by 107
miR-155 as a novel clinical target for hematological malignancies
Witten, L., & Slack, F. J. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz183 · Cited by 107
Dong, H.-F., Dai, W.-H., Ju, H.-X., Lu, H.-T., Wang, S., Xu, L.-P., Zhou, S.-F., Zhang, Y., & Zhang, X.-J. (2015) · ACS Applied Materials and Interfaces · doi:10.1021/acsami.5b02803 · Cited by 106
Liu, X., Liu, C., Zhou, J., Chen, C., Qu, F., Rossi, J. J., Rocchi, P., & Peng, L. (2014) · Nanoscale · doi:10.1039/c4nr04759a · Cited by 106
Tekedereli, İ., Alpay, S. N., Akar, U., Yuca, E., Ayugo-Rodriguez, C., Han, H.-D., Sood, A. K., Lopez‐Berestein, G., & Özpolat, B. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.45 · Cited by 106
Non-viral nanocarriers for siRNA delivery in breast cancer
Zhang, J., Li, X., & Huang, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.037 · Cited by 106
Systematic classification of non-coding RNAs by epigenomic similarity
Dozmorov, M. G., Giles, C. B., Koelsch, K. A., & Wren, J. D. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s14-s2 · Cited by 104
Recent advances in siRNA delivery for cancer therapy using smart nanocarriers
Zhang, P., An, K., Duan, X., Xu, H., Li, F., & Xu, F. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.042 · Cited by 103
Mohammadi, M., Salmasi, Z., Hashemi, M., Mosaffa, F., Abnous, K., & Ramezani, M. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.031 · Cited by 101
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 100
Conde, J., Ambrosone, A., Hernández, Y., Tian, F., McCully, M., Berry, C. C., Baptista, P. V., Tortiglione, C., & de la Fuente, J. M. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.008 · Cited by 96
Engel, J. B., Emons, G., Pinski, J., & Schally, A. V. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.685128 · Cited by 96
Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
Pecot, C. V., Wu, S. Y., Bellister, S. A., Filant, J., Rupaimoole, R., Hisamatsu, T., Bhattacharya, R., Maharaj, A., Azam, S. H., Rodriguez‐Aguayo, C., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0074 · Cited by 96
Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment
Rao, N. V., Yoon, H. Y., Han, H. S., Ko, H., Son, S., Lee, M., Lee, H., Jo, D., Kang, Y. M., & Park, J. H. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1112374 · Cited by 96
Non-viral nanocarriers for intracellular delivery of microRNA therapeutics
Bai, Z., Wei, J., Yu, C., Han, X., Qin, X., Zhang, C., Liao, W., Li, L., & Huang, W. (2019) · Journal of Materials Chemistry B · doi:10.1039/c8tb02946f · Cited by 94
Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer
Stegh, A. H., Petrosko, S. H., Meade, T. J., & Mirkin, C. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4 · Cited by 93
Non-viral based miR delivery and recent developments
Labatut, A. E., & Mattheolabakis, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.04.018 · Cited by 93
Givosiran: A Review in Acute Hepatic Porphyria
Syed, Y. Y. (2021) · Drugs · doi:10.1007/s40265-021-01511-3 · Cited by 93
Cited by
Bai, R., Li, Y., Jian, L., Yang, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 279
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
The landscape of nanoparticle-based siRNA delivery and therapeutic development
Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.005 · Cited by 230
Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy
Tang, Y., Liu, X., Sun, M., Xiong, S., Xiao, N., Li, J., He, X., & Xie, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071902 · Cited by 24
Sharma, S., Bhattacharya, S., Joshi, K., & Singh, S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05331-8 · Cited by 13
Metadata
- Authors
- Kara, G., Calin, G. A., & Ozpolat, B.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 182
- Pages
- 114113
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4206527368
- Cited by
- 411
- References
- 272
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.